Reviva Pharmaceuticals to be Delisted from Nasdaq, Moving to OTCQB
RVPH sits 34% above its 52-week low of $0.59 on light trading volume (0.3× avg).
Summary
Reviva Pharmaceuticals will be delisted from Nasdaq on May 14, 2026, after failing to meet the minimum bid price requirement, and its stock will begin trading on the OTCQB Venture Market.
Key Events · Corporate Governance and Compliance · RVPH
-
Nasdaq Delisting Confirmed
The company received a letter from the Nasdaq Hearings Panel confirming its common stock will be delisted from Nasdaq as of the open of trading on May 14, 2026, due to non-compliance with the $1.00 minimum bid price requirement.
-
Transition to OTCQB Venture Market
Beginning May 14, 2026, Reviva Pharmaceuticals' common stock will be quoted on the OTCQB Venture Market under its existing symbol 'RVPH'.
-
Significant Adverse Impacts Expected
The delisting is expected to materially and adversely impact the company by reducing stock liquidity and market price, limiting its ability to raise equity financing, impairing equity incentives, and potentially causing the stock to be classified as a 'penny stock'.
-
Failed Compliance Attempt
This delisting follows a 1-for-20 reverse stock split on March 9, 2026, which was implemented to address the Nasdaq minimum bid price requirement, indicating the failure of that strategy.
Analysis · RVPH · Life Sciences
Reviva Pharmaceuticals has received official notice of delisting from The Nasdaq Capital Market, effective May 14, 2026, due to its failure to maintain the minimum $1.00 bid price requirement. This follows a 1-for-20 reverse stock split on March 9, 2026, which was intended to regain compliance but ultimately failed. The delisting will significantly reduce the stock's liquidity, impair the company's ability to raise equity financing, and could lead to a further decline in market price, exacerbating the 'going concern' warning previously disclosed in its annual report.
At the time of this filing, RVPH was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2M. The 52-week trading range was $0.59 to $23.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.